Avalyn Pharma (AVLN): Developing 'Inhalation Therapies' for Rare Lung Diseases

Discovering a 'ten-bagger' in the biotechnology sector is the thrill of equity investing, where one pursues massive returns in exchange for high risk. Many drug discovery ventures take on the challenge of overcoming 'biological risk'—the discovery of new drug candidate molecules with entirely novel mechanisms of action. However, the success probability of this approach is statistically low, and there is no end to cases where, after investing enormous development funds, the drug fails in the final stages of clinical trials because its efficacy cannot be proven. In contrast, an approach that offers high investment appeal and an asymmetrically skewed risk-return profile (favorable to investors) is to 'innovate the administration route of existing effective drugs and capture market dominance by breaking through the barrier of side effects that could not be solved until now.'